Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stem Cell Agency Awards Research Grants

Published: Thursday, December 13, 2012
Last Updated: Thursday, December 13, 2012
Bookmark and Share
CIRM awards more than $36 million to research stem cell therapies for diseases that affect millions of Americans.

The funding is for the New Faculty Physician Scientist Translational Research Awards – an initiative that is designed to encourage and support the career development of promising physician scientists, a group with one foot in the lab and one foot in the clinic that are believed to be best at advancing therapies to clinical use.

“To do the best science you need to have the best and most effective clinical scientists,” says Alan Trounson, PhD, President of the agency. “This award helps physician scientists in the critical early stages of their career, providing them salary and research support for up to five years. Without that support many might not be able to establish an effective research career in science. With this support we are hoping to create a whole new group of world class researchers in California.”

Those winning awards include physician scientists who propose:

•    Using genetically-engineered stem cells to treat peripheral nerve disease, a painful and often debilitating condition
•    Developing cell-lines to help test the ability of drugs to reduce the incidence of preeclampsia, a serious complication affecting up to 8 percent of all pregnancies, endangering the life of both mother and unborn child
•    Trying to enhance the regeneration of inner ear sensory hair cells. Loss of these cells is a leading cause of deafness in everyone from newborns to the elderly
•    Using stem cells to repair damage to the intestines caused by irritable bowel disease, a painful condition that can cause intestinal failure and lead to cancer

“These new awards reflect the breadth of the vision that we have at California’s stem cell agency,” says Leeza Gibbons, a patient advocate member of the agency’s governing board, the Independent Citizens Oversight Committee (ICOC). “We are trying to both encourage new physician scientists and target diseases that affect millions of Americans and that currently have no cure.”

The ICOC received a briefing from Harold Shapiro, PhD from the Institute of Medicine (IOM) committee on its recently completed report on CIRM, including ten recommendations on steps the agency could take to improve its performance. The board members thanked the IOM for its diligent work and detailed study.

“This was a great opportunity for us to talk to Dr. Shapiro and his team and to gain a deeper understanding of the report and the rationale behind the recommendations,” says Jonathan Thomas, PhD, JD, Chair of the ICOC. “Over the next few weeks and months we will be holding extensive discussions to decide how best to proceed with the report and its recommendations.”

The ICOC also voted to approve amendments to the agency’s Conflict of Interest Code, requiring board members and staff to continue making the broadest level of financial disclosures on their annual statements of economic interests. The Board’s action satisfies the Political Reform Act, which requires state agencies to review their codes biennially.

In addition the ICOC approved $3 million in supplementary funding for ViaCyte, which is developing a therapy to treat type 1 diabetes. A Clinical Development Advisory Panel of outside experts recommended the supplementary funding after reviewing the ViaCyte project and praising it as one of the top programs they have seen with a strong potential to produce a therapy. The funds were needed to ensure the project stays on the path to clinical trials.

The board also discussed a new plan developed by CIRM management for “Industry Engagement and Commercialization.” The plan outlines four strategic objectives and cites existing and planned initiatives that support each one. The objectives include: attracting follow-on financing for CIRM-funded projects; support the creation, growth and relocation of companies in California; engage pharmaceutical companies in order to tap into their expertise; and actively assume a leadership role in promoting business in the field.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CIRM and Medical University of Warsaw Collaborate
Poland and California announce international collaboration to advance stem cell research toward cures.
Friday, November 21, 2014
Stem Cell Agency Invests $16 million To Fight Diabetes
The California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, today awarded $16 million to help accelerate the development of a treatment for type 1 diabetes.
Thursday, September 11, 2014
Stem Cell Agency Board Funds Cancer, Sickle Cell Disease and Vision Loss
Reflecting the progress being made in moving the most promising therapies out of the lab and into clinical trials, CIRM voted to approve $61 million in funding.
Monday, December 16, 2013
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
A New Way Out for Stem Cells
Researchers at North Carolina State University have discovered that therapeutic stem cells exit the bloodstream in a different manner than was previously thought.
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
Designing Potential AIDS Vaccine Candidates
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Anticancer Drug Stops Ebola Virus Molecule in its Tracks
A team of scientists from the University of Oxford have successfully mapped the structure of the Ebola virus molecule that drives the attack strategy and leads to fatal infections in humans.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!